Integrated Multiomics Validation of Key <i>MUC</i> Gene Expression for the Signature Biomarker in the Pakistani Cohort.

ABSTRACT:

Purpose

Pancreatic ductal adenocarcinoma (PDAC) is the 3^rd leading cause of cancer-related mortalities and has a poor prognosis, with a 5-year survival of 8%-9%. The major challenge associated with management of PDAC is delayed diagnosis. Diagnosis at an early stage can significantly increase the survival. Therefore, we used multiomics analysis to validate a novel signature biomarker of early-stage PDAC. The signature was derived from a computational analysis and subsequently validated in the Pakistani patient cohort, including patients with well-defined early-stage (I and II) PDAC.

Methods

With the aim of validating the signature biomarker (MUC3A/MUC4/MUC13/MUC16) as a potent early diagnostic and prognostic marker, a comprehensive anal

SUBMITTER: Naeem M 

PROVIDER: S-EPMC12547622 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature